TY - JOUR
T1 - Randomized trial to compare the effect of recombinant human FSH (follitropian alfa) with or without recombinant human LH in women udergoing assisted reproduction treatment
AU - Marrs, Richard
AU - Meldrum, D.
AU - Muasher, S.
AU - Schoolcraft, W.
AU - Werlin, L.
AU - Kelly, Eduardo
N1 - Copyright:
Copyright 2018 Elsevier B.V., All rights reserved.
PY - 2004/2
Y1 - 2004/2
N2 - Women undergoing intracytoplasmic sperm injection (ICSI) for male factor infertility were randomly assigned to receive ovarian stimulation in a long agonist protocol with a combination of recombinant human FSH (r-hFSH; Gonal-F®) and recombinant human LH (r-hLH; Luveris®) (n = 212) stating on day 6 of FSH stimulation until human chorionic gonadotrophin (HCG) at a daily fixed dose of 150 IU r-hLH, or with r-hFSH alone (n = 219). There was no significant difference in the number of metaphase II oocytes retrieved (10.3 versus 10.4) in patients treated with r-hFSH and r-hLH versus r-hFSH alone; however, more embryos were transferred in the LH-supplemented group (2.9 versus 2.8, P = 0.037). Overall, the implantation rates were 22.9 versus 27.0% in patients treated with r-hFSH and r-hLH versus with r-hFSH alone respectively (NS). The respective numbers of MII oocytes retrieved in patients <35 or ≥35 years were 11 versus 8.3 (P = 0.010) for patients treated with r-hFSH alone, and 10.7 versus 9.3 (NS) for those given supplemental r-hLH (150 IU) from day 6. Implantation rates in patients <35 years treated with r-hFSH were higher (30.7%) than those receiving r-hFSH and r-hLH, (23.5%) (P = 0.068). In patients ≥35 years, the implantation rates were 21.7% for those patients supplemented with 150 IU r-hLH from day 6 of stimulation versus 15.7% when treated with FSH alone (NS). Younger patients therefore do not seem to benefit from an LH-supplemented ovarian stimulation protocol, but women ≥35 years undergoing assisted reproduction may benefit from using r-hLH in addition to r-hFSH.
AB - Women undergoing intracytoplasmic sperm injection (ICSI) for male factor infertility were randomly assigned to receive ovarian stimulation in a long agonist protocol with a combination of recombinant human FSH (r-hFSH; Gonal-F®) and recombinant human LH (r-hLH; Luveris®) (n = 212) stating on day 6 of FSH stimulation until human chorionic gonadotrophin (HCG) at a daily fixed dose of 150 IU r-hLH, or with r-hFSH alone (n = 219). There was no significant difference in the number of metaphase II oocytes retrieved (10.3 versus 10.4) in patients treated with r-hFSH and r-hLH versus r-hFSH alone; however, more embryos were transferred in the LH-supplemented group (2.9 versus 2.8, P = 0.037). Overall, the implantation rates were 22.9 versus 27.0% in patients treated with r-hFSH and r-hLH versus with r-hFSH alone respectively (NS). The respective numbers of MII oocytes retrieved in patients <35 or ≥35 years were 11 versus 8.3 (P = 0.010) for patients treated with r-hFSH alone, and 10.7 versus 9.3 (NS) for those given supplemental r-hLH (150 IU) from day 6. Implantation rates in patients <35 years treated with r-hFSH were higher (30.7%) than those receiving r-hFSH and r-hLH, (23.5%) (P = 0.068). In patients ≥35 years, the implantation rates were 21.7% for those patients supplemented with 150 IU r-hLH from day 6 of stimulation versus 15.7% when treated with FSH alone (NS). Younger patients therefore do not seem to benefit from an LH-supplemented ovarian stimulation protocol, but women ≥35 years undergoing assisted reproduction may benefit from using r-hLH in addition to r-hFSH.
KW - Age
KW - Ovarian stimulation
KW - Recombinant FSH
KW - Recombinant LH
UR - http://www.scopus.com/inward/record.url?scp=1142287367&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=1142287367&partnerID=8YFLogxK
U2 - 10.1016/S1472-6483(10)60513-5
DO - 10.1016/S1472-6483(10)60513-5
M3 - Article
C2 - 14989794
AN - SCOPUS:1142287367
SN - 1472-6483
VL - 8
SP - 175
EP - 182
JO - Reproductive biomedicine online
JF - Reproductive biomedicine online
IS - 2
ER -